Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, had its shares halted from trading pending an announcement.
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- SecureCom buys Atmospheric, the Microsoft NZ Partner of the Year gone bust
- 9 Spokes accelerates efforts to get into US
- Sky will take a gamble and put Westworld, aka 'the next Game of Thrones' on Neon
- AngelEquity launches with three investment offers
- 'Real housewife' lawyers up, accuses Devoy of bullying, defamation
Most listened to
- 9 Spokes CEO Mark Estall on his company's progress since listing.
- BusinessNZ CEO Kirk Hope - Upbeat on the economy, but worried about private debt
- SecureCom director Greg Mikklesen on buying Atmospheric
- Balkan borders and Kashmir killings on Foreign Affairs Scope with Nathan Smith
- Ironically, Trump showed the lack of stamina he had accused Clinton of, says NBR's Rob Hosking